Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C.

J Pharmacol Exp Ther. 2018 Oct 5. pii: jpet.118.251645. doi: 10.1124/jpet.118.251645. [Epub ahead of print]

2.

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.

Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M.

Neurobiol Dis. 2018 Dec;120:21-33. doi: 10.1016/j.nbd.2018.08.018. Epub 2018 Aug 30.

PMID:
30172844
3.

An Alternative Approach to Estimate Solute Concentration: Exploiting the Information Embedded in the Solid Phase.

Bötschi S, Rajagopalan AK, Morari M, Mazzotti M.

J Phys Chem Lett. 2018 Aug 2;9(15):4210-4214. doi: 10.1021/acs.jpclett.8b01998. Epub 2018 Jul 13.

4.

Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.

Tozzi A, Durante V, Bastioli G, Mazzocchetti P, Novello S, Mechelli A, Morari M, Costa C, Mancini A, Di Filippo M, Calabresi P.

Neurobiol Dis. 2018 Oct;118:1-8. doi: 10.1016/j.nbd.2018.06.008. Epub 2018 Jun 13.

PMID:
29908325
5.

Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.

Tozzi A, Tantucci M, Marchi S, Mazzocchetti P, Morari M, Pinton P, Mancini A, Calabresi P.

Cell Death Dis. 2018 Feb 12;9(2):204. doi: 10.1038/s41419-017-0221-2.

6.

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M.

Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31.

PMID:
29232769
7.

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.

Morari M, Brugnoli A, Pisanò CA, Novello S, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M.

J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. doi: 10.1124/jpet.117.245100. Epub 2017 Nov 22.

PMID:
29167350
8.

Role of LRRK2 in the regulation of dopamine receptor trafficking.

Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, Iaccarino C.

PLoS One. 2017 Jun 5;12(6):e0179082. doi: 10.1371/journal.pone.0179082. eCollection 2017.

9.

Neural correlates of visuomotor adjustments during scaling of human finger movements.

Brand J, Michels L, Bakker R, Hepp-Reymond MC, Kiper D, Morari M, Eng K.

Eur J Neurosci. 2017 Jul;46(1):1717-1729. doi: 10.1111/ejn.13606.

PMID:
28503804
10.

Correction: Virtual Hand Feedback Reduces Reaction Time in an Interactive Finger Reaching Task.

Brand J, Piccirelli M, Hepp-Reymond MC, Morari M, Michels L, Eng K.

PLoS One. 2017 Apr 24;12(4):e0176655. doi: 10.1371/journal.pone.0176655. eCollection 2017.

11.

Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity.

Sacchi S, Novellis V, Paolone G, Nuzzo T, Iannotta M, Belardo C, Squillace M, Bolognesi P, Rosini E, Motta Z, Frassineti M, Bertolino A, Pollegioni L, Morari M, Maione S, Errico F, Usiello A.

Sci Rep. 2017 Apr 10;7:46288. doi: 10.1038/srep46288.

12.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

13.

Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain.

Rimessi A, Pavan C, Ioannidi E, Nigro F, Morganti C, Brugnoli A, Longo F, Gardin C, Ferroni L, Morari M, Vindigni V, Zavan B, Pinton P.

Neuropsychopharmacology. 2017 Jun;42(7):1491-1501. doi: 10.1038/npp.2017.20. Epub 2017 Jan 27.

14.

Parkinson's disease: no NOP, new hope.

Arcuri L, Mercatelli D, Morari M.

Oncotarget. 2017 Feb 7;8(6):8995-8996. doi: 10.18632/oncotarget.13710. No abstract available.

15.

Virtual Hand Feedback Reduces Reaction Time in an Interactive Finger Reaching Task.

Brand J, Piccirelli M, Hepp-Reymond MC, Morari M, Michels L, Eng K.

PLoS One. 2016 May 4;11(5):e0154807. doi: 10.1371/journal.pone.0154807. eCollection 2016. Erratum in: PLoS One. 2017 Apr 24;12 (4):e0176655.

16.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

17.

Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Collins LM, Dal Bo G, Calcagno M, Monzón-Sandoval J, Sullivan AM, Gutierrez H, Morari M, O'Keeffe GW.

Mol Neurobiol. 2016 Dec;53(10):7284-7297. Epub 2015 Dec 21.

PMID:
26687234
18.

Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.

Brugnoli A, Napolitano F, Usiello A, Morari M.

Neurobiol Dis. 2016 Jan;85:155-163. doi: 10.1016/j.nbd.2015.10.020. Epub 2015 Oct 29.

PMID:
26522958
19.

Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.

Volta M, Cataldi S, Beccano-Kelly D, Munsie L, Tatarnikov I, Chou P, Bergeron S, Mitchell E, Lim R, Khinda J, Lloret A, Bennett CF, Paradiso C, Morari M, Farrer MJ, Milnerwood AJ.

Parkinsonism Relat Disord. 2015 Oct;21(10):1156-63. doi: 10.1016/j.parkreldis.2015.07.025. Epub 2015 Aug 1.

PMID:
26282470
20.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E.

Prog Neurobiol. 2015 Sep;132:96-168. doi: 10.1016/j.pneurobio.2015.07.002. Epub 2015 Jul 21. Review.

PMID:
26209473
21.

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.

Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M.

Mov Disord. 2015 Nov;30(13):1728-38. doi: 10.1002/mds.26326. Epub 2015 Jul 24.

PMID:
26207892
22.

Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia.

Bido S, Solari N, Indrigo M, D'Antoni A, Brambilla R, Morari M, Fasano S.

Ann Clin Transl Neurol. 2015 Jun;2(6):662-78. doi: 10.1002/acn3.202. Epub 2015 Apr 24.

23.

Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors.

Blazer LL, Storaska AJ, Jutkiewicz EM, Turner EM, Calcagno M, Wade SM, Wang Q, Huang XP, Traynor JR, Husbands SM, Morari M, Neubig RR.

ACS Chem Neurosci. 2015 Jun 17;6(6):911-9. doi: 10.1021/acschemneuro.5b00063. Epub 2015 Apr 20.

PMID:
25844489
24.

d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain.

Cristino L, Luongo L, Squillace M, Paolone G, Mango D, Piccinin S, Zianni E, Imperatore R, Iannotta M, Longo F, Errico F, Vescovi AL, Morari M, Maione S, Gardoni F, Nisticò R, Usiello A.

Neurobiol Aging. 2015 May;36(5):1890-902. doi: 10.1016/j.neurobiolaging.2015.02.003. Epub 2015 Feb 12.

PMID:
25771393
25.
26.

Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.

Ravani L, Sarpietro MG, Esposito E, Di Stefano A, Sozio P, Calcagno M, Drechsler M, Contado C, Longo F, Giuffrida MC, Castelli F, Morari M, Cortesi R.

Mater Sci Eng C Mater Biol Appl. 2015 Mar;48:294-300. doi: 10.1016/j.msec.2014.12.014. Epub 2014 Dec 10.

PMID:
25579926
27.

Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Mabrouk OS, Viaro R, Volta M, Ledonne A, Mercuri N, Morari M.

J Neurosci. 2014 Sep 24;34(39):12953-62. doi: 10.1523/JNEUROSCI.4677-13.2014.

28.

Closed-loop neuromodulation of spinal sensorimotor circuits controls refined locomotion after complete spinal cord injury.

Wenger N, Moraud EM, Raspopovic S, Bonizzato M, DiGiovanna J, Musienko P, Morari M, Micera S, Courtine G.

Sci Transl Med. 2014 Sep 24;6(255):255ra133. doi: 10.1126/scitranslmed.3008325.

29.

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.

Longo F, Russo I, Shimshek DR, Greggio E, Morari M.

Neurobiol Dis. 2014 Nov;71:62-73. doi: 10.1016/j.nbd.2014.07.013. Epub 2014 Aug 6.

30.

LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex.

Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, Onofri F, Piccoli G.

Front Mol Neurosci. 2014 May 27;7:49. doi: 10.3389/fnmol.2014.00049. eCollection 2014.

31.

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.

Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG.

Sci Rep. 2014 Jan 16;4:3730. doi: 10.1038/srep03730.

32.

Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.

Viaro R, Calcagno M, Marti M, Borrelli E, Morari M.

Neuropharmacology. 2013 Sep;72:126-38. doi: 10.1016/j.neuropharm.2013.04.046. Epub 2013 May 3.

PMID:
23643745
33.

GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.

Mabrouk OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A, Parsons CG, Auberson YP, Morari M.

ACS Chem Neurosci. 2013 May 15;4(5):808-16. doi: 10.1021/cn400016d. Epub 2013 Apr 23.

34.

Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M.

J Neurosci. 2012 Nov 14;32(46):16106-19. doi: 10.1523/JNEUROSCI.6408-11.2012.

35.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.

Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x.

36.

L-dopa impairs proteasome activity in Parkinsonism through D1 dopamine receptor.

Morari M.

Mov Disord. 2012 May;27(6):706. No abstract available.

PMID:
22822491
37.

Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.

Costa C, Sgobio C, Siliquini S, Tozzi A, Tantucci M, Ghiglieri V, Di Filippo M, Pendolino V, de Iure A, Marti M, Morari M, Spillantini MG, Latagliata EC, Pascucci T, Puglisi-Allegra S, Gardoni F, Di Luca M, Picconi B, Calabresi P.

Brain. 2012 Jun;135(Pt 6):1884-99. doi: 10.1093/brain/aws101. Epub 2012 May 4.

PMID:
22561640
38.

Loss of cortical GABA terminals in Unverricht-Lundborg disease.

Buzzi A, Chikhladze M, Falcicchia C, Paradiso B, Lanza G, Soukupova M, Marti M, Morari M, Franceschetti S, Simonato M.

Neurobiol Dis. 2012 Aug;47(2):216-24. doi: 10.1016/j.nbd.2012.04.005. Epub 2012 Apr 17.

PMID:
22538221
39.

A hybrid tool for reaching and grasping rehabilitation: the ArmeoFES.

Crema A, McNaught A, Albisser U, Bolliger M, Micera S, Curt A, Morari M.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:3047-50. doi: 10.1109/IEMBS.2011.6090833.

PMID:
22254982
40.

Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study.

Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, Drechsler M, Mazzoni S, Menegatti E, Morari M, Cortesi R.

Eur J Pharm Biopharm. 2012 Feb;80(2):306-14. doi: 10.1016/j.ejpb.2011.10.015. Epub 2011 Oct 28.

PMID:
22061262
41.

In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.

Mela F, Marti M, Bido S, Cenci MA, Morari M.

Neurobiol Dis. 2012 Jan;45(1):573-82. doi: 10.1016/j.nbd.2011.09.015. Epub 2011 Oct 7.

PMID:
22001605
42.

Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.

Bido S, Marti M, Morari M.

J Neurochem. 2011 Sep;118(6):1043-55. doi: 10.1111/j.1471-4159.2011.07376.x. Epub 2011 Aug 5.

43.

NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid.

Fantin M, Morari M, Tison F, Fernagut PO.

Neurol Res. 2011 May;33(4):444-7. doi: 10.1179/1743132810Y.0000000002.

PMID:
21535946
44.

Spatially distributed sequential stimulation reduces fatigue in paralyzed triceps surae muscles: a case study.

Nguyen R, Masani K, Micera S, Morari M, Popovic MR.

Artif Organs. 2011 Dec;35(12):1174-80. doi: 10.1111/j.1525-1594.2010.01195.x. Epub 2011 Apr 19.

PMID:
21501192
45.

Progressive motor cortex functional reorganization following 6-hydroxydopamine lesioning in rats.

Viaro R, Morari M, Franchi G.

J Neurosci. 2011 Mar 23;31(12):4544-54. doi: 10.1523/JNEUROSCI.5394-10.2011.

46.

Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.

Volta M, Viaro R, Trapella C, Marti M, Morari M.

Exp Neurol. 2011 Mar;228(1):126-37. doi: 10.1016/j.expneurol.2010.12.024. Epub 2011 Jan 6.

PMID:
21215744
47.

Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.

Volta M, Mabrouk OS, Bido S, Marti M, Morari M.

J Neurochem. 2010 Dec;115(6):1543-55. doi: 10.1111/j.1471-4159.2010.07061.x. Epub 2010 Nov 11.

48.

Wearable neural prostheses. Restoration of sensory-motor function by transcutaneous electrical stimulation.

Micera S, Keller T, Lawrence M, Morari M, Popović DB.

IEEE Eng Med Biol Mag. 2010 May-Jun;29(3):64-9. doi: 10.1109/MEMB.2010.936547.

PMID:
20659859
49.

Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease.

Marti M, Sarubbo S, Latini F, Cavallo M, Eleopra R, Biguzzi S, Lettieri C, Conti C, Simonato M, Zucchini S, Quatrale R, Sensi M, Candeletti S, Romualdi P, Morari M.

Mov Disord. 2010 Aug 15;25(11):1723-32. doi: 10.1002/mds.23271.

PMID:
20589874
50.

Charge and energy minimization in electrical/magnetic stimulation of nervous tissue.

Jezernik S, Sinkjaer T, Morari M.

J Neural Eng. 2010 Aug;7(4):046004. doi: 10.1088/1741-2560/7/4/046004. Epub 2010 Jun 16.

PMID:
20551509

Supplemental Content

Loading ...
Support Center